Elucid Augments its Plaque-IQ Software Suite

Elucid has announced the availability of a new Lesion Inspection Tool for coronary and carotid plaque analysis in its Plaque-IQ software suite. The tool lets physicians interrogate lesion-specific composition and plaque burden across any vessel, which can help them better understand the patient risk profile and improve decision-making.

“The Lesion Inspection Tool provides a detailed view of plaque composition at the lesion level, beyond giving just overall plaque metrics,” said Jimmy Kerrigan, M.D., an interventional cardiologist with Ascension Saint Thomas Heart. “Because cardiovascular events like heart attacks occur at the lesion level, having the ability to characterize individual lesions enhances my understanding of a patient’s disease process and supports more informed clinical decision-making.”

With Plaque-IQ’s Lesion Inspection Tool, users can interrogate any lesion or region and access quantitative results for the specific segment. By providing precise quantification of plaque types at the lesion level, the tool lets physicians quantify high-risk features like lipid-rich necrotic core (LRNC). This objective and actionable data supports proactive, individualized treatment strategies, according to the company.

Elucid’s Plaque-IQ is the only plaque analysis technology trained and validated against objective ground truth histology, the gold standard for plaque characterization. Powered by CT-Virtual Histology (CT-VH), Plaque-IQ noninvasively quantifies and classifies coronary and carotid plaque and its components—including LRNC—offering direct insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies.

By focusing on true disease biology rather than population-based risk estimates, this approach can help physicians prioritize and personalize treatment for patients, Elucid bigwigs claim.

Elucid is a Boston-based artificial intelligence (AI) medical technology company developing technology that provides physicians with a more precise analysis of atherosclerosis (coronary and carotid plaque buildup), the root cause of cardiovascular disease. The company’s Plaque-IQ software helps physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ includes the only U.S. Food and Drug Administration-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to a heart attack and stroke. Elucid is also pursuing an indication for FFRCT, derived from its plaque algorithm, resulting in concordance between plaque and FFRCT. FFRCT helps physicians identify coronary blockages and the extent of a patient’s ischemia non-invasively.